Filing Flows

Filing Flows › Companies › 20/20 Biolabs › Cash flow

20/20 Biolabs cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$605K in Q2 2026 · −$2.8M over twelve months

Operating cash flow−$605K
Free cash flow−$605K
Cash conversion cycle-161 days

Analysis

In Q2 2026, 20/20 Biolabs generated −$605K of operating cash flow. That is $71K less than in Q2 2025 (−$534K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$2.8M; the largest uses were operating cash flow ($2.8M); besides operations, cash came from other financing ($5.2M), net borrowing (+) / repaid (−) ($1.2M); the cash balance rose by $3.5M.

Operating cash flow was −$605K against net income of −$1.5M. The largest differences: stock-based pay +$371K, accrued liabilities +$173K, receivables −$90K.

Its cash conversion cycle was -161 days (receivables 31 + inventory 23 − payables 214): suppliers fund its working capital.

Free cash flow

20/20 Biolabs: free cash flow by quarter20/20 Biolabs: free cash flow by quarter−$488KQ1 2025−$534KQ2 2025−$1.3MQ1 2026−$605KQ2 2026
Operating cash flow less capital spending.
20/20 Biolabs: operating cash flow against capital spending20/20 Biolabs: operating cash flow against capital spendingOperating cash flowCapital spending−$488K$0Q1 2025−$534K$0Q2 2025−$1.3M$0Q1 2026−$605K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$605K, Capital spending $0.

Cash runway and the debt wall

Cash & investments$1.0M
Debtnone
Net cash$1.0M
Cash runway4 months

20/20 Biolabs is burning cash: its operations consume cash, a free cash flow of −$2.8M a year at the current rate against $1.0M of cash and investments: a runway of about 4 months before any new financing.

Where the cash came from and went

20/20 Biolabs: sources (+) and uses (−) of cash, Q2 202620/20 Biolabs: sources (+) and uses (−) of cash, Q2 2026Other financing$940KOperating cash flow−$605KCash drawn (+) / kept (−)−$327KOther investing−$8K
20/20 Biolabs: sources (+) and uses (−) of cash, TTM to Q2 202620/20 Biolabs: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$5.2MCash drawn (+) / kept (−)−$3.5MOperating cash flow−$2.8MNet borrowing (+) / repaid (−)$1.2MNot reconciled−$13K

From profit to cash

20/20 Biolabs: net income to operating cash flow, Q2 202620/20 Biolabs: net income to operating cash flow, Q2 2026Net income−$1.5MDepreciation & amortization$12KStock-based pay$371KReceivables−$90KInventory−$7KPayables$46KAccrued liabilities$173KDeferred revenue$12KPrepaid and other assets$48KOperating cash flow−$605K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20263123214-161
Q1 20265134286-201

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$605K—−$327K−$605K
Q1 2026−$1.3M$250K−$3.2M−$1.3M
Q2 2025−$534K—$534K−$534K
Q1 2025−$488K$70K$226K−$488K

20/20 Biolabs: income statement and cash flow

20/20 Biolabs, Q2 2026: revenue $731K (+36% year over year), operating margin -170.3%. The chart follows the revenue to costs, profit and cash.

20/20 Biolabs: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.